Literature DB >> 22689089

Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique.

M Takada1, M Sugimoto, S Ohno, K Kuroi, N Sato, H Bando, N Masuda, H Iwata, M Kondo, H Sasano, L W C Chow, T Inamoto, Y Naito, M Tomita, M Toi.   

Abstract

Nomogram, a standard technique that utilizes multiple characteristics to predict efficacy of treatment and likelihood of a specific status of an individual patient, has been used for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. The aim of this study was to develop a novel computational technique to predict the pathological complete response (pCR) to NAC in primary breast cancer patients. A mathematical model using alternating decision trees, an epigone of decision tree, was developed using 28 clinicopathological variables that were retrospectively collected from patients treated with NAC (n = 150), and validated using an independent dataset from a randomized controlled trial (n = 173). The model selected 15 variables to predict the pCR with yielding area under the receiver operating characteristics curve (AUC) values of 0.766 [95 % confidence interval (CI)], 0.671-0.861, P value < 0.0001) in cross-validation using training dataset and 0.787 (95 % CI 0.716-0.858, P value < 0.0001) in the validation dataset. Among three subtypes of breast cancer, the luminal subgroup showed the best discrimination (AUC = 0.779, 95 % CI 0.641-0.917, P value = 0.0059). The developed model (AUC = 0.805, 95 % CI 0.716-0.894, P value < 0.0001) outperformed multivariate logistic regression (AUC = 0.754, 95 % CI 0.651-0.858, P value = 0.00019) of validation datasets without missing values (n = 127). Several analyses, e.g. bootstrap analysis, revealed that the developed model was insensitive to missing values and also tolerant to distribution bias among the datasets. Our model based on clinicopathological variables showed high predictive ability for pCR. This model might improve the prediction of the response to NAC in primary breast cancer patients.

Entities:  

Mesh:

Year:  2012        PMID: 22689089     DOI: 10.1007/s10549-012-2109-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Deformable registration for quantifying longitudinal tumor changes during neoadjuvant chemotherapy.

Authors:  Yangming Ou; Susan P Weinstein; Emily F Conant; Sarah Englander; Xiao Da; Bilwaj Gaonkar; Meng-Kang Hsieh; Mark Rosen; Angela DeMichele; Christos Davatzikos; Despina Kontos
Journal:  Magn Reson Med       Date:  2014-07-15       Impact factor: 4.668

2.  Urinary Polyamine Biomarker Panels with Machine-Learning Differentiated Colorectal Cancers, Benign Disease, and Healthy Controls.

Authors:  Tetsushi Nakajima; Kenji Katsumata; Hiroshi Kuwabara; Ryoko Soya; Masanobu Enomoto; Tetsuo Ishizaki; Akihiko Tsuchida; Masayo Mori; Kana Hiwatari; Tomoyoshi Soga; Masaru Tomita; Masahiro Sugimoto
Journal:  Int J Mol Sci       Date:  2018-03-07       Impact factor: 5.923

3.  Personalized chemotherapy selection for breast cancer using gene expression profiles.

Authors:  Kaixian Yu; Qing-Xiang Amy Sang; Pei-Yau Lung; Winston Tan; Ty Lively; Cedric Sheffield; Mayassa J Bou-Dargham; Jun S Liu; Jinfeng Zhang
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

4.  Salivary metabolomics with machine learning for colorectal cancer detection.

Authors:  Hiroshi Kuwabara; Kenji Katsumata; Atsuhiro Iwabuchi; Ryutaro Udo; Tomoya Tago; Kenta Kasahara; Junichi Mazaki; Masanobu Enomoto; Tetsuo Ishizaki; Ryoko Soya; Miku Kaneko; Sana Ota; Ayame Enomoto; Tomoyoshi Soga; Masaru Tomita; Makoto Sunamura; Akihiko Tsuchida; Masahiro Sugimoto; Yuichi Nagakawa
Journal:  Cancer Sci       Date:  2022-07-08       Impact factor: 6.518

5.  Machine learning models based on immunological genes to predict the response to neoadjuvant therapy in breast cancer patients.

Authors:  Jian Chen; Li Hao; Xiaojun Qian; Lin Lin; Yueyin Pan; Xinghua Han
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

6.  Can We Reliably Identify the Pathological Outcomes of Neoadjuvant Chemotherapy in Patients with Breast Cancer? Development and Validation of a Logistic Regression Nomogram Based on Preoperative Factors.

Authors:  Jian Zhang; Linhai Xiao; Shengyu Pu; Yang Liu; Jianjun He; Ke Wang
Journal:  Ann Surg Oncol       Date:  2020-10-23       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.